ACS Medication Strategy Decision Aid Tool
Clinical context
Select the patient and treatment factors to generate a structured antithrombotic strategy discussion.
Clinical context
Antithrombotic therapy after acute coronary syndrome balances prevention of recurrent ischemic events against bleeding. Selection and duration depend on ACS type, whether PCI or fibrinolysis was performed, stent and procedural factors, need for oral anticoagulation, contraindications, and patient-specific bleeding and ischemic risk.
Key decision points
- For ACS patients without high bleeding risk, aspirin plus an oral P2Y12 inhibitor for at least 12 months is the default strategy.
- For ACS patients undergoing PCI, ticagrelor or prasugrel is generally preferred to clopidogrel when appropriate.
- When long-term oral anticoagulation is required after PCI, aspirin is generally discontinued after 1–4 weeks, with continued oral anticoagulation plus a P2Y12 inhibitor, preferably clopidogrel.
- Prasugrel must not be used in patients with prior stroke or TIA. Age, body weight, contraindications, drug interactions, and bleeding risk also need review.
- Fibrinolysis pathways differ from primary PCI pathways; follow a dedicated STEMI fibrinolysis protocol and age-specific dosing guidance.
Important limitations
This aid is intentionally simplified and does not capture every factor required for prescribing. It does not calculate a validated bleeding score or assess renal function, age, body weight, prior gastrointestinal bleeding, hemoglobin, platelet count, drug interactions, planned surgery, coronary anatomy, or stent-thrombosis risk.
It does not provide complete loading-dose instructions for each P2Y12 inhibitor or a patient-specific anticoagulant dose. Confirm these details in the relevant guideline, product information, and local protocol before treatment.
References
Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025;151:e771–e862. doi:10.1161/CIR.0000000000001309.
Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023;44:3720–3826. doi:10.1093/eurheartj/ehad191.
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.